Form 4: IO Biotech CEO Acquires Shares in Open Market Transaction

IO Biotech's CEO, Mai-Britt Zocca, purchased 12,500 shares of common stock at $0.8096 per share on December 23, 2024.

Summary

• Mai-Britt Zocca, CEO of IO Biotech, acquired 12,500 shares of the company's common stock on December 23, 2024.
• The purchase price was $0.8096 per share.
• Following the transaction, Ms. Zocca directly owns 49,891 shares.
• She also indirectly owns 26,580 shares through Zocca Consulting ApS.
• Ms. Zocca disclaims beneficial ownership of the shares held by Zocca Consulting ApS except to the extent of her pecuniary interest.

Sentiment

Score: 7

Explanation: The document is a routine filing, but the CEO's purchase of shares is a positive signal, suggesting confidence in the company's future.

Positives

• The CEO's purchase of shares could be seen as a positive signal of confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders who trade their company's stock. It provides transparency into the trading activities of key personnel.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The transaction is relatively small in terms of total value, but the fact that the CEO is buying shares is a positive signal.

Stakeholder Impact

• The CEO's share purchase may positively influence investor sentiment.

Key Dates

Keywords

IO Biotech, insider trading, share purchase, CEO, Mai-Britt Zocca, common stock, Zocca Consulting ApS